Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age50-85
SponsorZhiming Yan

About this trial

This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN group and the control group. Throughout the study, both groups will take oral vitamin C and vitamin E supplements for a total of 28 days. Participants in the FSN group will receive four treatment sessions over two weeks. Both groups will be assessed at the end of the FSN treating period during the mid-study period, with ocular blood flow dynamics measured using OCTA, followed by a two-week follow-up. The primary outcome of this trial is the change in visual acuity from baseline to week 2, with secondary outcomes including visual field, visual function scale, macular thickness, central avascular zone area vascular density, and choroidal thickness.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • FSN+Vitamin supplement
  • Vitamin Supplements

Treatment groups

38 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Zhiming Yan

Lead sponsor

Guangdong Provincial Hospital of Traditional Chinese Medicine

Sponsor institution